PEAR News and Press, Pear Therapeutics Inc. From 01/26/23

BrightView expands its initiative with reSET ® and reSET-O ® to patients across Kentucky, Ohio, Delaware, Massachusetts, and Virginia Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescrip...

Pear’s prescription digital therapeutics (PDTs), reSET ® and reSET-O ® , are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023 Florida Medicaid is covering reSET ® and reSET-O ® for...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:...

Pear Therapeutics ( NASDAQ: PEAR ) said that the California Department of Health Care Services (DHCS) had selected it to track and distribute incentives for the recovery incentives to treat Medi-Cal members with stimulant use disorder. The pilot program will allow eligible members...

The California Department of Healt h Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California’s Contingency Management Program, to treat Medi-Cal members with stimulant use disorder DHCS in...

Pear Therapeutics ( NASDAQ: PEAR ) has signed an agreement with COEUS Healthcare to utilize the latter's outcomes and evidence-based reimbursement adjudication platform, COEBRA, to enable value-based contracting . The pact will facilitate states' access to value-based contracting ...

COEUS’ COEBRA™ Platform to Facilitate Value and Outcomes Based Agreements for Government and Commercial Payers Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digit...

Pear Therapeutics ( NASDAQ: PEAR ) and Spero Health have extended a partnership for the former to provide the latter prescription digital therapeutics for the treatment of substance use and opioid use disorders. Shares are up 4% in premarket trading. The extended arrangeme...

Spero Health, one of the nation’s largest office-based outpatient opioid treatment providers for individuals in recovery, to expand patient access to Pear’s prescription digital therapeutics (PDTs) for the treatment of substance use disorder (SUD) and opioid use disorder (OUD) ...

Alcohol is the most common substance use disorder (SUD), representing 70% of the more than 40 million people with SUD 1 New data from real-world use of reSET® demonstrate patients who use alcohol exhibit robust engagement, retention, and abstinence Pear Ther...